Logo

Incyte and MorphoSys Report First Patient Dosing in P-III inMIND Study for Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Share this

Incyte and MorphoSys Report First Patient Dosing in P-III inMIND Study for Relapsed or Refractory Follicular or Marginal Zone Lymphoma

Shots:

  • The first patient has been dosed in the P-IIII inMIND study assessing the efficacy and safety of tafasitamab vs PBO in combination with lenalidomide and rituximab in patients with r/r FL and MZL
  • The study is expected to enroll ~600 adults aged≥18yrs. with r/r FL or MZL. The 1EPs is PFS in the FL population and 2EPs are PFS and OS in the overall population as well as PET-CR at the EOT in the FL population
  • Tafasitamab is a humanized Fc-modified cytolytic CD19 targeting mAb and has received the US FDA’s ODD for FL

  Ref: Business Wire | Image: Morphosys

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions